It's Kylie Jenner vs Rihanna in a battle of the makeup brands. Kylie Cosmetics reportedly generated a whopping $420 million in sales within its first 18 months. But when Rihanna's Fenty Beauty line launched in September, with 40 shades of foundation, consumers applauded Ri-Ri's efforts at diversity.
Now, Jenner is launching 30 shades of foundation, and some fans are calling her out for copying. Allison Collins, Beauty Financial Editor at Women's Wear Daily, joins us to discuss.
Collins breaks down the main differences between the two brands' marketing plans. She also explains how more diversity in the industry--no matter where it comes from--is always good for the consumer.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
